Across TCGA pan-cancer cohorts, RPL7P60 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated RPL7P60 data layer.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher RPL7P60 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL7P60 expression acts as an unfavorable survival marker, although some lineages such as READ and PAAD show a favorable association.
READ, LGG, and PAAD are the cancer types where RPL7P60 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.